Clinical trials: EGFR Exon 21 Mutation
Advanced Non-small Cell Lung Cancer (NSCLC), EGFR Exon 19 Deletion Mutation
Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients
This is a multicenter, phase II exploratory clinical trial in untreated patients with EGFR-mutant non-small cell lung cancer (stages IIIB-IV) .All participants will receive oral befotertinib monotherapy for 3 weeks first, then…
- Conditions
- Advanced Non-small Cell Lung Cancer (NSCLC), EGFR Exon 19 Deletion Mutation, EGFR Exon 21 Mutation, EGFR Exon 21 L858R Mutation
- Trial name
- BE-MASTER (NCT07709585)
- Testing
- Befotinib, Pemetrexed + Cisplatin /Carboplatin
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Guangzhou University of Traditional Chinese Medicine
Advanced Stage Non Small Cell Lung Cancer
Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc
This study is a multicenter, randomized, open-label Phase II trial that compares reduced dose erlotinib 100mg daily and standard dose gefitinib 250mg daily in patients with advanced non-small cell lung cancer who harbor EGFR…
- Trial name
- NSCLC EGFR TKI (NCT01955421)
- Testing
- Erlotinib 100mg qd, Gefitinib 250mg qd
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Sun Yat-sen University
NSCLC
High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation
This randomized, open-label study is aimed to evaluate the efficacy of high-dose icotinib in treating advanced non-small cell lung cancer patients with positive EGFR 21 exon mutation.
- Trial name
- INCREASE (NCT02404675)
- Testing
- icotinib
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Thoracic Neoplasms
Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations
This is a randomized controlled trial to compare efficacy and safety between erlotinib and gefitinib in advanced NSCLC harboring EGFR exon 19 or 21 mutations.Eligible patients were randomized to receive erlotinib or gefitinib in…
- Trial name
- NCT01024413
- Testing
- erlotinib, gefitinib
- Where
- China
- Volunteers
- 256 people
- Sponsor
- Chinese Society of Lung Cancer